Biocon Biologics gets USFDA nod for its biosimilar to treat eye conditions – Healthcare News

Biocon Biologics Ltd (BBL) on Tuesday announced that the U.S. Food and Drug Administration (US FDA) has approved the Company’s first-to-file application for Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept.

According to the company’s statement, YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA (aflibercept).

“YESAFILI is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV). It is highly similar to the reference product Eylea (aflibercept). Data shows that YESAFILI has comparable quality, safety, and efficacy to Eylea,” the company said in a statement.

FLiRT KP.2, New Covid Variant

New COVID-19 variant alert! KP.2 can evade your immunity—Here’s how you can protect yourself

Covaxin, covaxin side effects, covaxin effect, covishield, bharat biotech, covid news, healthcare news, pharma news,

Covaxin Side-Effects: ICMR slams BHU study, calls it ‘misleading’; Demands retraction

Bharat Biotech, Covaxin, Covaxin side effects, Covaxin adverse effects, Bharat Biotech's vaccine, Coronavirus, Coronavirus vaccine, Covid-19, Covid, Covid vaccine, vaccine side effects, Astrazeneca, Covishield, Covishield row, Astrazeneca's vaccine, Covishield side effects

Covaxin side-effects: Over 30 percent recipients suffered from adverse effects of vaccine; Should you be worried?

Glenmark partners with Pfizer to launch oral drug for atopic dermatitis in India

Glenmark inks agreement with BeiGene for marketing and distribution of cancer drugs in India

The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States following a steady track record of approval in Europe (September 2023) and the United Kingdom (November 2023) where it was the first biosimilar aflibercept to be approved.

Moreover, the Company has secured a launch date in Canada of no later than July 1, 2025, under the terms of a settlement agreement.

“The FDA approval of YESAFILI (aflibercept) as the first interchangeable biological product to Eylea is a significant milestone for Biocon Biologics marking our entry into Ophthalmology, a new therapeutic area in the United States. YESAFILI is approved for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy. This approval builds on our successful track record of bringing the first interchangeable insulin, SEMGLEE, the first biosimilar Trastuzumab, OGIVRI, and the first biosimilar Pegfilgrastim, FULPHILA, to patients in the United States,” Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said in a statement.

19.8 million Americans are living with age-related macular degeneration (AMD) in the United States. In the U.S., sales of aflibercept were approximately $5.89 billion in 2023.


Leave a Reply

Your email address will not be published. Required fields are marked *